FHI Clinical Inc. has announced its intent to acquire Triclinium Clinical Development Proprietary Limited (TCD), a full-service, South African-based CRO and a subsidiary of EOH. With this transaction, FHI Clinical will employ more than 425 global staff representing 12 countries.
Headquartered in Centurion (Gauteng), South Africa, TCD has access to the South African market. South Africa accounts for most of the clinical trial activity in sub-Saharan Africa with the majority being infectious disease therapeutic studies. With approximately 285 employees already based in East and West Africa, FHI Clinical sees a unique opportunity to further expand its share of the ID market.
Current studies in TCD’s portfolio include both innovative vaccines and treatments spanning all phases of clinical research from single-dose Phase I trials to large multi-site Phase III and Phase IV trials.
FHI Clinical Announces Intent to Acquire South African-Based Triclinium Clinical Development (TCD)
Unlock Commercial Growth through Data-Driven Patient and HCP Insights
May 2nd 2025Leveraging data-driven patient and healthcare provider (HCP) insights, including social drivers of health (SDOH), is essential for life sciences companies to continuously improve patient engagement and commercial success. Mark Rodgers, AVP of Commercial Analytics at Inovalon, discusses how identifying treatment milestones, assessing HCP performance, and segmenting patient populations using SDOH data can drive targeted strategies that improve healthcare outcomes and market access
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.